http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices
-
Abbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
Abbott Raising Quarterly Dividend for 46th Straight Year
-
Abbott to Present at J.P. Morgan Healthcare Conference
-
Abbott (ABT) Says its MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
-
Abbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
-
Abbott (ABT) Reports FDA Clearance for its Alinity ci-series Next-generation Diagnostic Systems
-
Abbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems
-
Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery
-
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1]
-
Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.
-
A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott
-
Abbott Reports Third-Quarter 2017 Results
-
Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim™ DRG System
-
Abbott Completes Cash Tender Offer for Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
Abbott (ABT) Se to Close Alere (ALR) Takeover on October 3
-
Abbott Acquisition of Alere Set to Close on Tuesday, October 3, 2017
-
No More Routine Finger Sticks(1) for Americans with Diabetes: Abbott′s FreeStyle® Libre Approved in the U.S.
-
Abbott (ABT) Reports FDA Approval for MRI-Compatibility for Ellipse ICD
-
Abbott Secures FDA Approval for MRI-Compatibility for the Company's Ellipse™ ICD
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Absolute to Present at the Dougherty & Company Institutional Investor Conference
-
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
Abbott Declares 375th Consecutive Quarterly Dividend
-
FreeStyle® Libre Flash Glucose Monitoring Technology Gains Reimbursement Approval from the United Kingdom's National Health Service
-
Absolute to Present at the Dougherty & Company Institutional Investor Conference
-
Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index (DJSI)
-
Absolute Announces Approval of Normal Course Issuer Bid
-
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
Revolutionary Glucose Monitoring Technology FreeStyle® Libre Now Reimbursed Across Japan
-
Abbott (ABT) Initiates Study of AMPLATZER Device to Correct Congenital Heart Defect in Newborns
-
Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns
-
Abbott and the Abbott Fund Donate $1 Million to Support Hurricane Harvey Relief Efforts
-
Abbott (ABT) Reports FDA Approval for Full MagLev HeartMate 3 LVAD
-
Abbott Introduces HeartMate 3 Left Ventricular Assist System - the Latest Milestone In Therapy For Advanced Heart Failure Patients
-
Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per Patient
-
Abbott Reports Second-Quarter 2017 Results
-
Abbott Commences Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
-
Abbott (ABT), Bigfoot Biomedical Enter Pact to Develop Breakthrough Diabetes Technologies
-
Abbott and Bigfoot Biomedical Announce Collaboration to Develop Breakthrough Diabetes Technologies
-
Abbott Secures Health Canada License for FreeStyle® Libre System for People with Diabetes
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
Abbott Declares 374th Consecutive Quarterly Dividend
-
Abbott (ABT) Receives CE Mark for TactiCath Contact Force Ablation Catheter, Sensor Enabled
-
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
-
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
-
Abbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes

